Infinity Pharmaceuticals Inc (INFI)

1.60
NASDAQ : Health Care
Prev Close 1.60
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.24 / 10.85
Avg Volume 1.50M
Exchange NASDAQ
Shares Outstanding 49.59M
Market Cap 81.32M
EPS -2.60
P/E Ratio 0.30
Div & Yield N.A. (N.A)

Latest News

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate

Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint

Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint

Analysts cut valuation estimates for Infinity Pharmaceuticals after a disappointing drug study.

Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study

Analysts cut valuation estimates after a disappointing drug study. 

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Why Infinity Pharmaceuticals (INFI) Stock Is Tanking Today

Why Infinity Pharmaceuticals (INFI) Stock Is Tanking Today

Infinity Pharmaceuticals (INFI) stock is plunging after the company announced a restructuring following disappointing drug-study results.

Morning Movers: BIDU, WGP, NERV, INFI

Stocks were falling slightly in premarket trading Tuesday as oil continued its six-day descent.

Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma

Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma

- Infinity and AbbVie in Discussions to Explore Possible Options for the Duvelisib Collaboration -

Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies

Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies

- Campaign Designed to Educate and Engage Community and Academic Oncologists on the Role of the Tumor Microenvironment in B-Cell Malignancies -

Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings

Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings

-- Preliminary Data from CONTEMPO, a Phase 1b/2 Combination Study Evaluating Duvelisib in Treatment-Naive Patients with Follicular Lymphoma, to Be Presented at EHA --

Infinity Pharmaceuticals is Now Oversold (INFI)

Infinity Pharmaceuticals is Now Oversold (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

IPI-549 Alters The Immune-Suppressive Microenvironment And Enhances The Activity Of Checkpoint Inhibitors In Preclinical Models

IPI-549 Alters The Immune-Suppressive Microenvironment And Enhances The Activity Of Checkpoint Inhibitors In Preclinical Models

-- Preclinical Data for IPI-549 Presented at AACR Annual Meeting 2016 --

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Short Interest Falls 21.2% For INFI

Short Interest Falls 21.2% For INFI

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 1,155,480 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 4,282,662, a decrease of 21.25% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Infinity Pharmaceuticals Enters Oversold Territory (INFI)

Infinity Pharmaceuticals Enters Oversold Territory (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity Pharmaceuticals Stock Sees Short Interest Fall 27.8%

Infinity Pharmaceuticals Stock Sees Short Interest Fall 27.8%

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 2,163,821 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 5,615,623, a decrease of 27.81% since 12/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Infinity Pharmaceuticals Is Now Oversold (INFI)

Infinity Pharmaceuticals Is Now Oversold (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.